A validated analytical method detects and characterizes aggregate formation in liraglutide under stress conditions, helping ensure the quality and safety of this GLP-1 peptide drug.
Validated for specificity, accuracy, precision, linearityThe SEC-LC-UV/HRMS method meets rigorous analytical validation standards, making it suitable for routine quality control monitoring of liraglutide aggregates during manufacturing and storage.
What the researchers found
A validated size-exclusion chromatography method (SEC-LC-UV/HRMS) was developed to detect and characterize aggregates in the GLP-1 peptide drug liraglutide under various stress conditions. Photolytic, thermal, freeze-thaw, and mechanical shaking stress all induced different levels of aggregation. The study also evaluated how common pharmaceutical excipients and surfactants affect liraglutide aggregation and stability over time, providing guidance for formulation development.
Why it matters
Peptide drug aggregation is a critical quality concern — aggregates can reduce drug efficacy and potentially cause immune reactions in patients. As GLP-1 drugs like liraglutide become some of the most prescribed medications globally, ensuring their stability and quality is essential. This analytical method helps manufacturers and biosimilar developers monitor and prevent aggregation during production and storage.
The numbers in context
SEC-LC-UV/HRMS method · validated for specificity, accuracy, precision, linearity · photolytic, thermal, freeze-thaw, shaking stress conditions tested · excipient impact on aggregation evaluated
How the study worked
Size exclusion chromatography coupled with UV detection and high-resolution mass spectrometry was developed and validated to separate and identify liraglutide aggregates. Liraglutide was subjected to various stress conditions (light, heat, freeze-thaw, shaking). Excipients and surfactants commonly used in peptide formulations were tested for their impact on aggregation levels and physicochemical stability.
Who was studied
Analytical chemistry study on liraglutide drug product (no patient population)
What this study cannot tell us
This is a purely analytical/quality control study with no clinical or biological outcomes. The stress conditions used in the lab may not perfectly replicate real-world storage and handling. The study focused on liraglutide; applicability to other GLP-1 RA peptides would need separate validation. Aggregate immunogenicity was not assessed.
How to read the evidence
This is a validated analytical method development study. The analytical validation is rigorous and meets pharmaceutical quality control standards, though it addresses drug quality rather than clinical outcomes.
When this study was published
Published in 2024, this method supports current quality control needs as liraglutide biosimilars enter the market alongside the innovator product.
The bigger picture
As GLP-1 drugs become some of the highest-revenue medications in history, ensuring product quality at scale is a massive challenge. With biosimilar competition emerging for liraglutide and other peptide drugs, robust analytical methods for detecting aggregation are essential for both innovator companies and generic manufacturers. This method contributes to the analytical toolkit needed to guarantee that patients receive safe, effective peptide medications.
Questions still open
- Can this SEC-LC-UV/HRMS method be adapted for other GLP-1 agonists like semaglutide and tirzepatide?
- Which excipients best prevent liraglutide aggregation during long-term storage?
- Do the aggregates detected by this method pose actual immunogenicity risks in patients?
Common questions
Why does peptide aggregation matter for drug safety?
What causes liraglutide to aggregate?
Read the original research
Size-exclusion LC-UV/HRMS based method for the analysis of aggregates in synthetic GLP-1 analog liraglutide and evaluation of excipient impact on aggregation.
Biomedical chromatography : BMC, 38(10), e5983
Citation
Badgujar, Devendra; Bawake, Sanket; Chawathe, Ashwini; Sharma, Nitish. (2024). Size-exclusion LC-UV/HRMS based method for the analysis of aggregates in synthetic GLP-1 analog liraglutide and evaluation of excipient impact on aggregation.. Biomedical chromatography : BMC, 38(10), e5983. https://doi.org/10.1002/bmc.5983